MONDAY, OCTOBER 11, 2010

7:30-8:00  Breakfast

8:00-8:10  Introductions and Welcome

Session 1-Immune Targeting of ALL
Chair: Rick O’Reilly, MSKCC, New York, NY

8:10-8:35  Rick O’Reilly, MSKCC, New York, NY
Adoptive Immune Therapies Employing Antigen-Specific T Cells of Desired HLA Restriction for Treatment of Life-Threatening Viral Diseases Following HLA-Disparate Cord Blood and Adult HSC Transplants

8:35-9:00  Hans Stauss, Royal Free Hospital, London, UK
Engineering WT1 TCRs

9:00-9:25  Max Topp, University of Würzburg, Germany
Blinatumomab, A Bispecific Antibody Targeting CD19, Induces Haematological and Molecular Remissions in Patients with Various B-Cell Malignancies

9:25-9:50  Alan Wayne, NCI, Bethesda, MD
Anti-CD22 Immunotoxins for Acute Lymphoblastic Leukemia

9:50-10:05  Break

Session 2-Chimeric Antigen Receptor for Hematology Malignancies
Chair: Malcolm Brenner, TCH, TMH, BCM, Houston, TX

10:05-10:30  Michel Sadelain, MSKCC, New York, NY
Targeting B Malignancies with Autologous CD19-Targeted T Cells: The MSKCC Experience

10:30-10:55  Barbara Savoldo, TCH, TMH, BCM, Houston, TX
The Effects of Co-stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed CAR in Human Subjects with B-Cell Malignancies

10:55-11:20  Carl June, University of Pennsylvania, Philadelphia, PA
CD19 CARS: Status at the University of Pennsylvania

11:20-11:45  Oliver Press, University of Washington, Seattle, WA
Adoptive Immunotherapy for Indolent and Mantle Cell Lymphomas Using Genetically Modified Autologous CD20-Specific T Cells

11:45-12:15  Panel Discussion - Future of CD19/20 Targeted CARs
12:15-1:15 **Lunch and Poster Session**

**Session 3-Immune Targeting of Pediatric Solid Tumors**  
Chair: Crystal Mackall, NCI, Bethesda, MD

1:15-1:40 *Paul Sondel, University of Wisconsin, Madison, WI*  
Cell-Mediated Destruction of Neuroblastoma Facilitated by Anti-GD2 Reagents CH14.18 and HU14.18-IL2

1:40-2:05 *Nai-Kong Cheung, MSKCC, New York, NY*  
Next Generation Monoclonal Antibodies for Solid Tumors: Improving Effector Functions by Enhancing Affinities for Antigen and Fc Receptor

2:05-2:30 *Crystal Mackall, NCI, Bethesda, MD*  
Toward Exportable Consolidative Immunotherapy for Solid Tumors

2:30-2:55 *Stephan Grupp, CHOP, Philadelphia, PA*  
Immune Reconstitution Therapies

2:55-3:20 *Stanley Riddell, FHCRC, Seattle, WA*  
IL15 to Support Adoptive Immunotherapy

3:20-3:35 **Break**

**Session 4-Cars for Solid Tumors**  
Chair: Gianpietro Dotti, TCH, TMH, BCM, Houston, TX

3:35-4:00 *Stephen Gottschalk, TCH, TMH, BCM, Houston, TX*  
T Cells Redirected Against HER2 for the Adoptive Immunotherapy of HER2-Positive Malignancies

4:00-4:25 *Michael Jensen, Seattle Children’s Hospital, Seattle, WA*  
Targeting Brain Tumors

4:25-4:50 *Chrystal Louis, TCH, TMH, BCM, Houston, TX*  
Treatment of High Risk Neuroblastoma with Autologous T Lymphocytes Engineered to Recognize GD2

4:50-6:30 **Poster Session/Refreshments**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30-8:00</td>
<td><strong>Breakfast</strong></td>
<td></td>
</tr>
<tr>
<td>8:00-8:25</td>
<td>Session 5-Enhancing Graft versus Leukemia for Pediatric Cancers</td>
<td>Rupert Handgretinger, University of Tübingen, Germany</td>
</tr>
<tr>
<td></td>
<td>Chair: Rupert Handgretinger, University of Tübingen, Germany</td>
<td></td>
</tr>
<tr>
<td>8:25-8:50</td>
<td>NK Cell Therapies Post-AlloSCT</td>
<td>Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy</td>
</tr>
<tr>
<td>8:50-9:15</td>
<td>Graft vs. Leukemia</td>
<td>Terry Fry, NCI, Bethesda, MD</td>
</tr>
<tr>
<td>9:15-9:40</td>
<td>Vaccines and Allogeneic SCT</td>
<td>Peter Bader, University of Frankfurt, Germany</td>
</tr>
<tr>
<td>9:40-10:00</td>
<td>Allogeneic Stem Cell Transplantation in Children and Adolescents with Solid Tumors</td>
<td>Antonio Di Stasi, TCH, TMH, BCM, Houston, TX</td>
</tr>
<tr>
<td>10:00-10:25</td>
<td>CASPALLO: Phase I Clinical Trial of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene after Haploidentical Stem Cell Transplantation</td>
<td>Peter Adamson, CHOP, COG, Philadelphia, PA</td>
</tr>
<tr>
<td>10:25-10:40</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:40-11:05</td>
<td>Session 6-Overcoming Hurdles of Immunotherapy</td>
<td>Hideho Okada, University of Pittsburgh, Pittsburgh, PA</td>
</tr>
<tr>
<td>11:05-11:30</td>
<td>Vaccinations Targeting Glioma-Associated Antigens (GAAs) in Pediatric Patients with Glioma</td>
<td>Stefaan Van Gool, Katholieke University, Leuven, Belgium</td>
</tr>
<tr>
<td>11:30-11:55</td>
<td>Immunotherapy for High Grade Glioma: Preclinical Research and Perspectives</td>
<td>Laurence Cooper, MDACC, Houston, TX</td>
</tr>
<tr>
<td>11:55-12:15</td>
<td>Potential Pathways for Development of Immunotherapies in COG</td>
<td>Rebecca Gardner, FHCRC, Seattle, WA</td>
</tr>
</tbody>
</table>
12:15-12:35  Shakeel Modak, MSKCC, New York, NY
Suppression of Human Anti-Mouse Antibody Response by Rituximab Plus Cyclophosphamide Permits Continuation of Anti-GD2 Immunotherapy

12:35-12:55  Matthias Wölfl, University of Würzburg, Germany
Primed Tumor-Reactive Multifunctional CD62L+ Human CD8+ T-Cells for Immunotherapy

1:00-2:00  Lunch

Session 7-NK Cells, NKT Cells and γδ Cells
Chair: Dario Campana, St. Jude Children’s Research Hospital, Memphis, TN

2:00-2:25  Dario Campana, St. Jude Children’s Research Hospital, Memphis, TN
Engineering Natural Killer Cells

2:25-2:50  Mike Verneris, University of Minnesota, Minneapolis, MN
Adoptive Therapy with Natural Killer Cells

2:50-3:15  Leonid Metelitsa, TCH, BCM, Houston, TX
Anti-tumor Potential of Type-1 NKT Cells Against CD1d+ and CD1d− Pediatric Tumors

3:15-3:40  Claudia Rossig, University of Münster, Germany
Activated γδ T Cells for Cellular Immunotherapy of Childhood Cancer

3:40-3:55  Break

Session 8-Immunotherapies: Beyond Phase I Studies
Chair: Helen Heslop, TCH, TMH, BCM, Houston, TX

3:55-4:15  Ann Leen, TCH, TMH, BCM, Houston, TX
Most Closely HLA-Matched Allogeneic Virus Specific CTL to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV after HSCT

4:15-4:40  Catherine Bollard, TCH, TMH, BCM, Houston, TX
Administration of Tumor-Specific Cytotoxic T Lymphocytes for Patients with EBV-Associated Lymphomas – Moving to Phase II Studies

4:40-5:00  John Chen, VA Medical Center, BCM, Houston, TX
What will complex biologicals need to do to prove themselves cost-effective?

5:00-5:15  Malcolm Brenner, TCH, TMH, BCM, Houston, TX
Closing Remarks

5:15  Adjourn